- Home
- / CXL Ophthalmics
CXL Ophthalmics
Total Funding
$32 M
CXL Ophthalmics Summary
Company Summary
- Overview
- CXL Ophthalmics is a clinical-stage company specializing in the treatment of corneal diseases. It develops minimally invasive treatments using the EpiSmart approach preventing disease progression. The company offers treatment with devices such as EpiPrep, RiboStat, and UVA device.
- Type
- Private
- Status
- Active
- Founded
- 2012
Table of Contents
Key People
Michael W. Belin, Chief Medical Officer
Edward Parsons, Chief Operating Officer
Alan F. Russell, Chief Development & Regulatory Officer
